Literature DB >> 33411265

Association between C-reactive protein and carotid plaque in mild-to-moderate idiopathic pulmonary fibrosis.

Andrea Sonaglioni1, Antonella Caminati2, Roberto Lipsi3, Michele Lombardo1, Sergio Harari3,4,5.   

Abstract

An association between C-reactive protein (CRP) levels and carotid plaque has never been investigated in idiopathic pulmonary fibrosis (IPF). The aim of this study was to evaluate the extent of carotid atherosclerosis in mild-to-moderate IPF and to assess its relationship to serum CRP. This observational retrospective case-control study included 60 consecutive IPF patients (73.8 ± 6.6 years, 45 males) and 60 matched controls, examined between Sep 2017 and Jan 2019. All patients underwent CRP assessment and a carotid Doppler ultrasonography. CRP levels were significantly higher in IPF patients than controls (0.2 ± 0.09 mg/dl vs 0.09 ± 0.04 mg/dl, p < 0.0001). A total of 46 plaques were detected, with higher prevalence in IPF patients than controls (38 vs 8, p < 0.0001). On univariate logistic regression the main variables independently associated with carotid plaque were: age (HR 1.09, 95% CI 1.03-1.16, p = 0.006), hypertension duration (HR 1.05, 95% CI 1.01-1.09, p = 0.01), diabetes duration (HR 1.09, 95% CI 1.01-1.18, p = 0.03), LDL-cholesterol (HR 1.07, 95% CI 1.04-1.10, p < 0.0001) and finally CRP levels (HR 1.73, 95% CI 0.59-5.00, p < 0.0001). Multivariate logistic regression analysis revealed that LDL-cholesterol (HR 1.05, 95% CI 1.01-1.08, p = 0.009) and CRP levels (HR 1.43, 95% CI 0.39-5.19, p < 0.0001) retained statistical significance. Common carotid artery-intima media thickness was significantly correlated with CRP levels in IPF patients (r = 0.86). SerumCRP might represent both an early marker and a potential therapeutic target for carotid atherosclerosis in mild-to-moderate IPF.
© 2021. Società Italiana di Medicina Interna (SIMI).

Entities:  

Keywords:  C-reactive protein; Carotid atherosclerosis; Idiopathic pulmonary fibrosis

Year:  2021        PMID: 33411265     DOI: 10.1007/s11739-020-02607-6

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  42 in total

Review 1.  Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots.

Authors:  Steven D Nathan; Paul W Noble; Rubin M Tuder
Journal:  Am J Respir Crit Care Med       Date:  2007-01-25       Impact factor: 21.405

2.  Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis.

Authors:  Christopher J Lettieri; Steven D Nathan; Scott D Barnett; Shahzad Ahmad; Andrew F Shorr
Journal:  Chest       Date:  2006-03       Impact factor: 9.410

3.  Risk factors for cardiovascular disease in people with idiopathic pulmonary fibrosis: a population-based study.

Authors:  William Dalleywater; Helen A Powell; Richard B Hubbard; Vidya Navaratnam
Journal:  Chest       Date:  2015-01       Impact factor: 9.410

Review 4.  Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue.

Authors:  Antonella Caminati; Chiara Lonati; Roberto Cassandro; Davide Elia; Giuseppe Pelosi; Olga Torre; Maurizio Zompatori; Elisabetta Uslenghi; Sergio Harari
Journal:  Eur Respir Rev       Date:  2019-10-01

5.  Prevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis.

Authors:  Steven D Nathan; Ashwin Basavaraj; Cristina Reichner; Oksana A Shlobin; Shahzad Ahmad; Joseph Kiernan; Nelson Burton; Scott D Barnett
Journal:  Respir Med       Date:  2010-03-02       Impact factor: 3.415

Review 6.  Cardiac manifestations of idiopathic pulmonary fibrosis.

Authors:  Abhinav Agrawal; Isha Verma; Varun Shah; Abhishek Agarwal; Rutuja R Sikachi
Journal:  Intractable Rare Dis Res       Date:  2016-05

7.  Impairment of pulmonary function is an independent risk factor for atrial fibrillation: the Takahata study.

Authors:  Yoko Shibata; Tetsu Watanabe; Daisuke Osaka; Shuichi Abe; Sumito Inoue; Yoshikane Tokairin; Akira Igarashi; Keiko Yamauchi; Tomomi Kimura; Hiroyuki Kishi; Yasuko Aida; Keiko Nunomiya; Takako Nemoto; Masamichi Sato; Tsuneo Konta; Sumio Kawata; Takeo Kato; Takamasa Kayama; Isao Kubota
Journal:  Int J Med Sci       Date:  2011-08-29       Impact factor: 3.738

Review 8.  Idiopathic Pulmonary Fibrosis for Cardiologists: Differential Diagnosis, Cardiovascular Comorbidities, and Patient Management.

Authors:  Johan van Cleemput; Andrea Sonaglioni; Wim A Wuyts; Monica Bengus; John L Stauffer; Sergio Harari
Journal:  Adv Ther       Date:  2018-12-15       Impact factor: 3.845

9.  Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.

Authors:  Ganesh Raghu; Martine Remy-Jardin; Jeffrey L Myers; Luca Richeldi; Christopher J Ryerson; David J Lederer; Juergen Behr; Vincent Cottin; Sonye K Danoff; Ferran Morell; Kevin R Flaherty; Athol Wells; Fernando J Martinez; Arata Azuma; Thomas J Bice; Demosthenes Bouros; Kevin K Brown; Harold R Collard; Abhijit Duggal; Liam Galvin; Yoshikazu Inoue; R Gisli Jenkins; Takeshi Johkoh; Ella A Kazerooni; Masanori Kitaichi; Shandra L Knight; George Mansour; Andrew G Nicholson; Sudhakar N J Pipavath; Ivette Buendía-Roldán; Moisés Selman; William D Travis; Simon Walsh; Kevin C Wilson
Journal:  Am J Respir Crit Care Med       Date:  2018-09-01       Impact factor: 21.405

10.  Epidemiology of Idiopathic Pulmonary Fibrosis in Northern Italy.

Authors:  Sergio Harari; Fabiana Madotto; Antonella Caminati; Sara Conti; Giancarlo Cesana
Journal:  PLoS One       Date:  2016-02-03       Impact factor: 3.240

View more
  1 in total

1.  Incremental prognostic value of arterial elastance in mild-to-moderate idiopathic pulmonary fibrosis.

Authors:  Andrea Sonaglioni; Antonella Caminati; Gian Luigi Nicolosi; Michele Lombardo; Sergio Harari
Journal:  Int J Cardiovasc Imaging       Date:  2022-02-01       Impact factor: 2.357

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.